Literature DB >> 1490338

Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor.

A W Taylor1, J W Streilein, S W Cousins.   

Abstract

The aqueous humor of the eye contains factors that regulate immunological responses within the immunosuppressive ocular microenvironment. Besides TGF-beta, the proteins in the low molecular weight (< 3500 Da) fraction of normal aqueous humor are also immunosuppressive. The low molecular weight fraction of aqueous humor inhibits IFN-gamma production and proliferation of antigen-stimulated lymph node cells. Neuropeptides are one possible family of low molecular weight factors in aqueous humor. Through the utilization of an antigen capturing enzyme-assay, the immunosuppressive neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) was detected in normal aqueous humor of humans, rabbits, and mice. The mean concentration of alpha-MSH in normal aqueous humor of humans was 20 +/- 3 pM, of rabbits 11 +/- 1 pM, of BALB/c mice 16 +/- 3 pM, and of C57BL/6 mice 14 +/- 3 pM. These physiological concentrations of alpha-MSH inhibited the production of IFN-gamma by antigen-stimulated lymph node cells. In contrast to the low molecular weight fraction, alpha-MSH did not inhibit proliferation. There was a 26% recovery of IFN-gamma production when alpha-MSH was absorbed from the low molecular weight fraction. The results demonstrate neuropeptides to be constitutive components of normal aqueous humor and that factors with the capability of differential regulation of effector T-cell activity may be present within the immunosuppressive ocular microenvironment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1490338     DOI: 10.3109/02713689208999545

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  62 in total

1.  Characterization of phenotype and cytokine profiles of T cell lines derived from vitreous humour in ocular inflammation in man.

Authors:  M Muhaya; V L Calder; H M Towler; G Jolly; M McLauchlan; S Lightman
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

Review 2.  Immunologic privilege of the eye.

Authors:  J W Streilein
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Mechanism related to reduction of intraocular pressure by melanocortins in rabbits.

Authors:  N Naveh; A Kaplan-Messas; J Marshall
Journal:  Br J Ophthalmol       Date:  2000-12       Impact factor: 4.638

Review 4.  Novel mechanisms of class II major histocompatibility complex gene regulation.

Authors:  Michael Radosevich; Santa Jeremy Ono
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

5.  Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells.

Authors:  Jeong-Hyeon Sohn; Puran S Bora; Hye-Jung Suk; Hector Molina; Henry J Kaplan; Nalini S Bora
Journal:  Nat Med       Date:  2003-01-06       Impact factor: 53.440

6.  The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation.

Authors:  Koh-Hei Sonoda; Taiji Sakamoto; Hong Qiao; Toshio Hisatomi; Toru Oshima; Chikako Tsutsumi-Miyahara; Mark Exley; Steven P Balk; Masaru Taniguchi; Tatsuro Ishibashi
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

7.  Ocular immune privilege in the year 2010: ocular immune privilege and uveitis.

Authors:  Andrew W Taylor; Henry J Kaplan
Journal:  Ocul Immunol Inflamm       Date:  2010-12       Impact factor: 3.070

8.  The immune privileged retina mediates an alternative activation of J774A.1 cells.

Authors:  Chun H Lau; Andrew W Taylor
Journal:  Ocul Immunol Inflamm       Date:  2009 Nov-Dec       Impact factor: 3.070

9.  Diminishment of alpha-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages.

Authors:  Dayu Li; Andrew W Taylor
Journal:  J Leukoc Biol       Date:  2008-04-03       Impact factor: 4.962

10.  Decay accelerating factor is essential for successful corneal engraftment.

Authors:  A Esposito; B Suedekum; J Liu; F An; J Lass; M G Strainic; F Lin; P Heeger; M E Medof
Journal:  Am J Transplant       Date:  2010-01-05       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.